3 years ago

Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation: Results of the PRESS trial

Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation: Results of the PRESS trial
Gyung‐Min Park, Jae‐Hwan Lee, Si Wan Choi, Jin‐Ok Jeong, Eun‐Seok Shin, Jang‐Whan Bae, Hyuck‐Jun Yoon, Kyung Tae Jung, Ju Yeol Baek, Woong Gil Choi, Rak Kyeong Choi, Sung‐Ho Her, Jin Bae Lee, Jon Suh, Jae Beom Lee, Se‐Whan Lee, In‐Ho Chae, So‐Yeon Choi, In‐Whan Seong

Background

There are limited data on the clinical value of routine postdilatation using noncompliant balloons after contemporary drug‐eluting stent implantation.

Hypothesis

Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation could provide better clinical outcomes.

Methods

We randomly assigned 1774 patients with coronary artery disease to undergo additional high‐pressure postdilatation using noncompliant balloons and moderate‐pressure dilatation using stent balloons after everolimus‐eluting stent implantation. The primary endpoint was a composite of death, myocardial infarction (MI), stent thrombosis, and target vessel revascularization (TVR) 2 years after randomization.

Results

The study was discontinued early owing to slow enrollment. In total, 810 patients (406 patients in the high pressure group and 404 in the moderate pressure group) were finally enrolled. At 2 years, the primary endpoint occurred in 3.6% of patients in the high pressure group and in 4.4% of those in the moderate pressure group (P = .537). In addition, no significant differences were observed between the two groups in the occurrence of an individual end point of death (0.8% in the high pressure group vs 1.5% in the moderate group, P = .304), MI (0.2% vs 0.5%, P = .554), stent thrombosis (0% vs 0.2%, P = .316), or TVR (2.8% vs 2.6%, P = .880).

Conclusions

The strategy of routine postdilatation using noncompliant balloons after everolimus‐eluting stent implantation did not provide incremental clinical benefits.

Open access
You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.